申请人:Novartis AG
公开号:US11370763B2
公开(公告)日:2022-06-28
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
在一个方面,以式 AA 的化合物或其药学上可接受的盐为特征。式 AA 中所示变量如权利要求书中所定义。式 AA 的化合物是 NLRP3 活性调节剂,因此可用于治疗代谢性疾病(如 2 型糖尿病、动脉粥样硬化、肥胖或痛风)、中枢神经系统疾病(如阿尔茨海默病、多发性硬化症、多发性脊髓侧索硬化症、多发性硬化症等)。阿尔茨海默病、多发性硬化症、肌萎缩侧索硬化症或帕金森病)、肺部疾病(如哮喘、慢性阻塞性肺病或肺特发性纤维化)、肝脏疾病(如 NASH 综合征、病毒性肝炎或肝硬化)、胰腺疾病(如急性胰腺炎或慢性胰腺炎)、肾脏疾病(如急性肾损伤或慢性肾损伤)。急性肾损伤或慢性肾损伤)、肠道疾病(如克罗恩病或溃疡性结肠炎)、皮肤病(如牛皮癣)、肌肉骨骼疾病(如硬皮病)、血管疾病(如巨细胞动脉炎)、骨骼疾病(如骨关节炎、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症、骨质疏松症等眼病(如青光眼或黄斑变性)、病毒感染引起的疾病(如艾滋病病毒或艾滋病)、自身免疫性疾病(如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎)、癌症或衰老。